HCA Healthcare, Inc.HCA
HCA Healthcare, Inc. Financial Overview 2021–2025
HCA Healthcare has ruthlessly consolidated its ownership base, reducing its share count from 0.31 billion in FY2021 to 0.22 billion at the end of FY2025. This aggressive capital allocation underscores a high-volume operating model that leverages significant debt to fund capacity expansion while consistently outpacing inflationary pressures. The company’s financial trajectory reflects this durability, with total revenue expanding from $58.8 billion in FY2021 to $75.6 billion in FY2025, driven by resilient demand for inpatient and outpatient services.
Operational efficiency remained a key driver in FY2025, where net income climbed to $6.78 billion, supported by a 2.9% rise in equivalent admissions and 4.0% growth in revenue per admission. Management successfully defended margins against labor headwinds, lowering salaries and benefits to 43.5% of revenue in FY2025 from 44.1% the prior year. However, leverage remains a central risk factor; the company carried $44.6 billion in total debt as of Q1 2025, necessitating robust cash generation to service liabilities while funding the repurchase of 26.7 million shares throughout FY2025. At the close of the fiscal year, the market valued these results at a market cap of $104.9 billion, with the stock trading at $466.86 or 16.5x trailing earnings.
Recent Developments (Q3 and Q4 2025)
HCA Healthcare delivered a robust Q3 2025, driving revenue up 9.6% to $19.2 billion and net income 29.4% higher to $1.64 billion. Management effectively controlled labor expenses, which dropped to 43.6% of revenue in the quarter compared to 45.0% in the prior year. Capital allocation accelerated significantly post-quarter; the company issued $3.25 billion in senior notes in October 2025 and subsequently authorized a new $10 billion share repurchase program in January 2026, alongside a dividend increase to $0.78 per share.
Bulls highlight the $10 billion buyback authorization and expanding margins as evidence of a superior operating model. Bears caution that legislative headwinds, specifically the "One Big Beautiful Bill Act" and expiring enhanced premium tax credits, threaten future reimbursement stability. As of the February 9, 2026 report, the stock traded at $502.05, valuing the company at 17.7x trailing earnings.
What to watch: Medicare reimbursement changes from the OBBBA; expiration of enhanced premium tax credits.
Rev
$75.60B
FY2025
NI
$6.78B
FY2025
EPS
$28.70
FY2025
OCF
$12.64B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
HCA Healthcare, Inc. 8-K Report, Financial Results (Jan 27, 2026)
HCA Healthcare, Inc. (HCA) filed an 8-K on January 27, 2026, reporting its financial and operational results for the fourth quarter and full year ended December 31, 2025. While the 8-K itself primarily references a press release (Exhibit 99.1) for detailed financial performance, it directly discloses two significant capital allocation decisions by the Board of Directors. These decisions are a substantial $10 billion share repurchase authorization and the declaration of a quarterly cash dividend of $0.78 per share. These announcements indicate a strong focus on returning capital to shareholders. The large share repurchase program suggests management's confidence in the company's valuation and future prospects, potentially signaling a belief that the stock is undervalued. The consistent dividend payment further reinforces a commitment to shareholder returns. Investors will want to closely examine the detailed financial results in the referenced press release to understand the underlying performance driving these capital allocation decisions.
HCA Healthcare, Inc. 8-K Report, Material Agreement (Oct 31, 2025)
HCA Healthcare, Inc. (HCA) announced the successful completion of a significant public offering of senior notes, raising a total of $3.25 billion. The offering was structured across four tranches with varying maturities and coupon rates: $500 million of 4.300% Senior Notes due 2030, $1 billion of 4.600% Senior Notes due 2032, $1 billion of 4.900% Senior Notes due 2035, and $750 million of 5.700% Senior Notes due 2055. These notes are guaranteed by the parent company, HCA Healthcare, Inc., and represent senior unsecured obligations of the subsidiary issuer. The proceeds from this offering will likely be used to fund general corporate purposes or existing debt refinancing, though specific use of proceeds is not detailed in this filing. The company has also entered into an underwriting agreement with several prominent financial institutions to facilitate this issuance. This move indicates HCA's ongoing strategy to manage its capital structure and potentially fund future growth or operational needs.
HCA Healthcare, Inc. 8-K Report, Corporate Update (Oct 27, 2025)
HCA Healthcare, Inc. (HCA) announced through a press release dated October 27, 2025, the commencement of a proposed public offering of senior unsecured notes by its wholly owned subsidiary, HCA Inc. This offering aims to raise capital, and the specific use of proceeds will be detailed further. Concurrently, HCA Inc. has elected to redeem all of its $1.500 billion of 5.875% senior notes due 2026. This redemption is contingent upon the successful receipt of proceeds from the new note offering and is scheduled for November 26, 2025. This strategic move suggests HCA is likely refinancing existing debt, potentially to lower its interest expenses or extend its maturity profile.
HCA Healthcare, Inc. 8-K Report, Financial Results (Oct 24, 2025)
HCA Healthcare, Inc. (HCA) has filed an 8-K report on October 24, 2025, primarily to announce its third-quarter results for the period ending September 30, 2025, via a press release (Exhibit 99.1). While the full financial details are within the press release, this filing serves as official notification of the company's operational and financial performance for the quarter. Investors should refer to the press release for comprehensive information regarding revenue, profitability, and any forward-looking guidance. In addition to the quarterly results, HCA Healthcare announced a quarterly cash dividend of $0.72 per share. This dividend payment, scheduled for December 29, 2025, to stockholders of record on December 15, 2025, demonstrates the company's commitment to returning capital to its shareholders. This dividend declaration is a significant event for income-focused investors.
HCA Healthcare, Inc. 8-K Report, Financial Results (Jul 25, 2025)
HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing its second quarter 2025 results and announcing a quarterly cash dividend. The press release, attached as Exhibit 99.1, is the primary source of operational and financial information for the quarter ended June 30, 2025. Investors should review this press release for specific financial performance metrics and commentary on the company's condition. In addition to its quarterly results, HCA's Board of Directors has declared a quarterly cash dividend of $0.72 per share. This demonstrates a commitment to returning capital to shareholders and provides income-generating potential for investors holding the stock. The dividend payment is scheduled for September 30, 2025, to shareholders of record on September 16, 2025.
View all 8-K filings →